CHDI
Listed here are over 1,035 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS
Results of the citalopram to enhance cognition in Huntington disease trial
Sanders SS, Mui KK, Sutton LM, Hayden MR
Identification of binding sites in huntingtin for the huntingtin interacting proteins HIP14 and HIP14L
Mealer RG, Murray AJ, Shahani N, Subramaniam S, Snyder SH
Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy
Sajjad MU, Green EW, Miller-Fleming L, Hands S, Herrera F, Campesan S, Khoshnan A, Outeiro TF, Giorgini F, Wyttenbach A
DJ-1 modulates aggregation and pathogenesis in models of Huntington's disease
Bard J, Wall MD, Lazari O, Arjomand J, Munoz-Sanjuan I
Advances in huntington disease drug discovery: novel approaches to model disease phenotypes
Dodel R, Jonsson B, Reese JP, Winter Y, Martinez-Martin P, Holloway R, Sampaio C, Ruzicka E, Hawthorne G, Oertel W, Poewe W, Stebbins G, Rascol O, Goetz CG, Schrag A
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson`s disease
Buonincontri G, Wood NI, Puttick SG, Ward AO, Carpenter TA, Sawiak SJ, Morton AJ
Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine
J Huntingtons Dis
January 31, 2014
3 (1) :25-32
3 (1) :25-32
PMID: 24744818
PMCID: 3986496
DOI: 10.3233/JHD-130083
Ness V, Bestgen AK, Saft C, Beste C
Changes in cognitive control in pre-manifest Huntington's disease examined using pre-saccadic EEG potentials - a longitudinal study
Muralidharan P, Fishbaugh J, Johnson HJ, Durrleman S, Paulsen JS, Gerig G, Fletcher PT
Diffeomorphic shape trajectories for improved longitudinal segmentation and statistics
Anderson KE, Divino V, DeKoven M, Langbehn D, Warner JH, Giuliano J, Lee WC
Interventional differences among Huntington`s disease patients by disease progression in commercial and medicaid populations
Vodicka P, Lim J, Williams DT, Kegel KB, Chase K, Park H, Marchionini D, Wilkinson S, Mead T, Birch H, Yates D, Lyons K, Dominguez C, Beconi M, Yue Z, Aronin N, DiFiglia M
Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice
Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Caviness J, Biglan K, Olson B, Paulsen JS
Does interval between screening and baseline matter in HD cognitive clinical trials?
Sutcliffe JS, Beaumont V, Watson JM, Chew CS, Beconi M, Hutcheson DM, Dominguez C, Munoz-Sanjuan I
Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)
Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I, Howland D
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington`s disease
Cachope R, Cheer JF
Local control of striatal dopamine release
Macdonald D, Tessari MA, Boogaard I, Smith M, Pulli K, Szynol A, Albertus F, Lamers MB, Dijkstra S, Kordt D, Reindl W, Herrmann F, McAllister G, Fischer DF, Munoz-Sanjuan I
Quantification assays for total and polyglutamine-expanded huntingtin proteins
Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study
Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, Munoz-Sanjuan I
The PDE1/5 inhibitor SCH-51866 does not modify disease progression in the R6/2 mouse model of Huntington`s Disease
Todd D, Gowers I, Dowler SJ, Wall MD, McAllister G, Fischer DF, Dijkstra S, Fratantoni SA, van de Bospoort R, Veenman-Koepke J, Flynn G, Arjomand J, Dominguez C, Munoz-Sanjuan I, Wityak J, Bard JA
A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington`s disease
Burli RW, Luckhurst CA, Aziz O, Matthews KL, Yates D, Lyons KA, Beconi M, McAllister G, Breccia P, Stott AJ, Penrose SD, Wall M, Lamers M, Leonard P, Muller I, Richardson CM, Jarvis R, Stones L, Hughes S, Wishart G, Haughan AF, O`Connell C, Mead T, McNeil H, Vann J, Mangette J, Maillard M, Beaumont V, Munoz-Sanjuan I, Dominguez C
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington`s disease
Träger U, Magnusson A, Lahiri Swales N, Wild E, North J, Lowdell M, Björkqvist M
JAK/STAT signalling in Huntington's disease immune cells
Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR
A systematic review and meta-analysis of clinical variables used in Huntington disease research
Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I
Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study
Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI, TRACK-HD Investigators
Corpus callosal atrophy in premanifest and early Huntington's disease
Deng YP, Wong T, Bricker-Anthony C, Deng B, Reiner A
Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice
Busan S, Weeks KM
Role of context in RNA structure: flanking sequences reconfigure CAG motif folding in huntingtin exon 1 transcripts
Biochemistry
November 19, 2013
52 (46) :8219-25
52 (46) :8219-25
PMID: 24199621
PMCID: 4890576
DOI: 10.1021/bi401129r
Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA
Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease
Paulsen JS, Smith MM, Long JD, PREDICT HD investigators and Coordinators of the Huntington Study Group
Cognitive decline in prodromal Huntington Disease: implications for clinical trials
Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D
Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis
Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, Wanker EE, Olson EN, Luthi-Carter R, van der Putten H, Beaumont V, Bates GP
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration
Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C, Goetz CG, Leentjens AF, Martinez-Martin P, Pavy-Le Traon A, Post B, Sampaio C, Stebbins GT, Weintraub D, Schrag A
Task force report: scales for screening and evaluating tremor: critique and recommendations
Wójtowicz AM, Dvorzhak A, Semtner M, Grantyn R
Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3
Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, Goniotaki D, Morgan S, Mirzaei N, Mazarakis ND
Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum
Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, Liu D, Westervelt HK, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Regional atrophy associated with cognitive and motor function in prodromal Huntington disease
J Huntingtons Dis
October 1, 2013
2 (4) :477-89
2 (4) :477-89
PMID: 25062732
PMCID: 4412155
DOI: 10.3233/JHD-130076
Liu J, Pendergraff H, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, Manoharan M, Hu J, Corey DR
RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression
Nucleic Acids Res
October 1, 2013
41 (18) :8788-801
41 (18) :8788-801
PMID: 23887934
PMCID: 3794577
DOI: 10.1093/nar/gkt594
Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, Green EW, Dhulkhed D, Kyriacou CP, Giorgini F
Glutathione peroxidase activity is neuroprotective in models of Huntington's disease
Georgiou-Karistianis N, Poudel GR, Dominguez DJf, Langmaid R, Gray MA, Churchyard A, Chua P, Borowsky B, Egan GF, Stout JC
Functional and connectivity changes during working memory in Huntington`s disease: 18 month longitudinal data from the IMAGE-HD study
Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing N, Williams JK, Long JD, Paulsen JS, Predict-Hd Investigators, Coordinators of the Huntington Study Group
Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study
Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM, Huntington Study Group PHAROS Investigators
HTRF analysis of soluble huntingtin in PHAROS PBMCs